Transgenically produced antithrombin III

• US 7,928,064 B2
• Filed: 11/14/2005
• Issued: 04/19/2011
• Est. Priority Date: 02/21/1995
• Status: Expired due to Fees

• Current Assignee: rEVO Biologics, Inc. (Agence des Participations de l’Etat)
• Original Assignee: GTC Biotherapeutics, Inc.
• Inventors: DiTullio, Paul, Cole, Edward S., Meade, Harry M.
• Primary Examiner(s): Crouch; Deborah
• Application Number:
  US11/284,585
• Publication Number:
  US 20080176786A1
• Time in Patent Office: 1,982 Days
• Field of Search: None
• US Class Current: 514/14.7
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: C07K 14/8128 Antithrombin III
• CPC Class Codes: Y10S 530/832 Milk; colostrum

Abstract

This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.

Claims

1. A method of treating a subject having an antithrombin III (ATIII) deficiency or inflammation, comprising:

administering to the subject a non-human mammal mammary gland produced recombinant antithrombin III (ATIII).

2. The method of claim 1, wherein the mammary gland produced antithrombin III (ATIII) is produced in the mammary glands of a transgenic goat.

3. The method of claim 1, wherein said non-human mammal is produced by microinjection procedures.

4. The method of claim 1, wherein said antithrombin (III) is at least 90% pure as determined by ELISA.

5. The method of claim 1, wherein the antithrombin III (ATIII) glycosylation varies from plasma-derived antithrombin III (ATIII) by the increased presence of GalNAc and reduction of sialic acid.